-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Reiterates Buy on ArriVent BioPharma, Maintains $29 Price Target

Benzinga·10/16/2026 18:23:02
Diffusion vocale
BTIG analyst Jeet Mukherjee reiterates ArriVent BioPharma (NASDAQ:AVBP) with a Buy and maintains $29 price target.